Reach Us +443308085114
Novel Methods For Improved Biologics Productivity By Integrated Process Techniques | 10435
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Novel methods for improved biologics productivity by integrated process techniques

2nd International Conference and Exhibition on Biowaivers & Biosimilars

Ashesh Kumar

Accepted Abstracts: J Bioanal Biomed

DOI: 10.4172/1948-593X.S1.011

Efficient production of therapeutic protein requires an integrated upstream and downstream process. Further, process analytical techniques (PAT) are utilized to control variations and to modulate flexibility in the system to operate it efficiently. Use of GMP compatible, scalable process as well as genetically stable clones facilitates consistent titers and quality of desired product. Any changes for improving the upstream process which results into higher fermentation/ bioreactor yields are always a challenge for the downstream purification team to follow it through to achieve high product yields. In a unique effort, we have studied and demonstrated that changes in the fermentation at scale up level can be systematically visualized at microscopic level with the help of optimized method of preparation of cells under electron microscopy (EM) techniques. These subtle changes in the fermentation can be then fine-tuned to have higher productivity which is very difficult (if not impossible) to achieve. The study also allowed, quantifying the level of production of inclusion bodies and their densities, and to relate them to number of cells expressing them after induction. A novel method thus allows, better optimized fermentation conditions, for achieving higher titers. Study indicates that availability of genetically stable and robust clone for production of therapeutic protein helps in the integrations.
Ashesh Kumar is Director-Biologics & Licensing at Paras Biopharmaceuticals Finland. Prior to this, he was Head of Biopharmaceuticals at Medipolis GMP Oy Finland for six years, where he led a team of process scientists and was responsible for development of a scalable production technology for a biosimilar analog insulin technology, and successfully licensing it to a European partner. He is a Ph.D. in Biosciences & Biotechnology from Indian Institute of Technology, Roorkee, India with 15 years of Biopharma industry experience on biosimilars and their scale up production. His research is published in peer reviewed international journals. He has also authored and edited a number of books and is member of various international groups in USA and EU.